PAOG Signs Clinical Research Organization (CRO) to Advance Respiratory Cannabis Treatment Through Regulatory Approval
- Written by Newsfile
Sandusky, Ohio--(Newsfile Corp. - October 23, 2020) - PAO Group, Inc. (OTC Pink: PAOG) today announced executing a master services agreement with a clinical research organization in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG signed the agreement yesterday, prior to the comprehensive corporate update scheduled for publication today and included in its entirety below.
Corporate Update
Less than 90 days ago, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY) and began to transform the company into a cannabis biopharmaceutical development operation. The company has come a long way very quickly and management believes the rapid progress has been possible based on the merits of the research backing RespRx.
RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled, "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT".
In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated affecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.
The CRO agreement signed yesterday is a year long agreement and a major step forward to advancing RespRx through the regulatory approval process. PAOG plans to make a joint announcement next week with the CRO company.
As previously announced, and in addition to the CRO agreement announced today, PAOG continues to develop pharmaceutical research and development relationships in Puerto Rico's burgeoning, recently reinvigorated pharmaceutical industry. An announcement of an anticipated key contract in Puerto Rico is expected soon.
Part of PAOG's pharmaceutical development strategy includes the development of a proprietary hemp cultivar. In addition to acquiring RespRx from KALY, PAOG recently acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA). PAOG is building a partnership with PURA in conjunction with PAOG's new hemp cultivation business. PAOG has announced working with PURA's new hemp processing facility in Farmersville, Texas where the two companies will partner on the construction of a greenhouse for cultivating pharmaceutical grade hemp and a lab for CBD extraction.
PAOG's partnership includes making PURA shareholders, shareholders of PAOG. PAOG's purchase of PURA included a PAOG stock issued to PURA shareholders in a dividend distribution. The timing of the execution of the dividend has been impacted by the overall large volume of work surrounding the integration of the RespRx and hemp cultivation operations and the prioritization of establishing a CRO contract. PAOG and PURA management have committed time together next week to get the dividend process over the speed bump. A joint progress announcement is planned for a week from today, next Friday, October 30, 2020.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION:
Jim DiPrima888-272-6472info@pao.group[2]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66743[3]
References
- ^ www.paogroupinc.com (www.newsfilecorp.com)
- ^ info@pao.group (www.newsfilecorp.com)
- ^ https://www.newsfilecorp.com/release/66743 (www.newsfilecorp.com)
